Thyroid dysfunction in preterm infants born before 32 gestational weeks

BMC Pediatrics

Table 2 Neonatal comorbidities of the levothyroxine nontreatment and treatment groups

	Nontreatment N = 145	Treatment N = 35	p	Adjusted p^*
Intraventricular hemorrhage (≥grade III) (%)	7 (4.8)	5 (14.3)	0.059	–
Symptomatic patent ductus arteriosus (%)	81 (55.9)	24 (68.6)	0.187	–
Necrotizing enterocolitis (≥stage II) (%)	13 (9.0)	3 (8.6)	1.000	–
Late-onset sepsis (%)	12 (8.3)	6 (17.1)	0.124	–
Bronchopulmonary dysplasia (%)	73 (50.3)	19 (54.3)	0.710	–
LASER therapy for retinopathy of prematurity (%)	39 (26.9)	11 (31.4)	0.675	–
Periventricular leukomalacia (%)	14 (9.7)	8 (22.9)	0.044	0.015

Values are presented as numbers (%)
^*Adjusted for variables including gestational age and birth weight percentile used as categorical variables (23–25 weeks, 26–28 weeks, 29–31 weeks for gestational age; < 33%, 33–67, > 67% for birth weight percentile), cesarean section, maternal pregnancy-induced hypertension and periventricular leukomalacia

ISSN: 1471-2431